Summary by Futu AI
SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorder therapies, has announced the enrollment and dosing of the first five patients in its clinical trial for SCI-210, a treatment for autism spectrum disorder (ASD). The trial is being conducted at the Soroka Medical Center in Israel and involves a double-blind, randomized, and placebo-controlled study to compare the efficacy of SCI-210 against standard CBD monotherapy in managing ASD symptoms. SciSparc plans to enroll 60 subjects aged between five and 18 over a 20-week period. The company aims to commercialize SCI-210 in Israel first, followed by other countries, pending regulatory approvals. The trial's primary efficacy metrics include the Aberrant Behavior Checklist-Community, the Clinical Global Impressions-Improvement...Show More